<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00486044</url>
  </required_header>
  <id_info>
    <org_study_id>IA0116</org_study_id>
    <secondary_id>1K23AG026752-01</secondary_id>
    <nct_id>NCT00486044</nct_id>
  </id_info>
  <brief_title>Evaluating Simvastatin's Potential Role in Therapy</brief_title>
  <acronym>ESPRIT</acronym>
  <official_title>Effect of Statins on Pathobiology of Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Paul Beeson Faculty Scholars Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The John A. Hartford Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Atlantic Philanthropies</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Starr Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Federation for Aging Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see how simvastatin, a cholesterol-lowering drug, affects
      processes related to the development of Alzheimer's disease, including: 1) levels of a
      substance called beta-amyloid-42 found in the spinal fluid surrounding the brain, 2) blood
      flow in the brain, 3) inflammation in the brain, and 4) cognitive function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Some studies suggest that statin medications, which are a group of cholesterol-lowering
      medicines, may help prevent Alzheimer's disease. However, this has not been proven in humans.
      The purpose of this study is to see how simvastatin affects a substance in the spinal fluid
      around the brain called beta-amyloid-42 which is thought to contribute to Alzheimer's
      disease. This study also evaluates whether simvastatin improves regional brain blood flow (on
      magnetic resonance imaging [MRI]), reduces inflammation, and improves cognitive function.

      The ESPRIT study was a 9-month randomized, controlled clinical trial that randomized 100
      middle-aged adults with a parental history of Alzheimer's disease. Participants were
      randomized to simvastatin 40 mg for one month then 80 mg daily or matching placebo tablets.
      Fifty of the ESPRIT subjects participated in the MRI sub-study.

      Participants had the following data collected: fasting blood tests (baseline and months 3 and
      9), medical history and medication questionnaires (each visit), study medication side effect
      review (all visits), lumbar puncture procedure (baseline and month 9), memory testing
      (baseline and months 3 and 9), and MRI (baseline and month 9 in 50 sub-study participants).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Cerebrospinal Fluid (CSF) Beta-amyloid-42</measure>
    <time_frame>baseline and 9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Regional Cerebral Blood Flow on MRI</measure>
    <time_frame>baseline and 9 months</time_frame>
    <description>Mean changes noted in posterior cingulate cortex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inflammatory Markers</measure>
    <time_frame>baseline and 9 months</time_frame>
    <description>Change noted in serum high-sensitivity c-reactive protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Cognitive Performance</measure>
    <time_frame>Baseline and 9 months</time_frame>
    <description>Change in Hopkins Verbal Learning Test Delayed Recall
The Hopkins Verbal Learning Test Delayed Recall score is the raw number of words recalled at Trial 4, adjusted for years of education and age. This is a 12-item word list test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>simvastatin 40 mg nightly for 1 month then 80 mg nightly for 8 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo tablet nightly for 9 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>40 mg tablet each night for one month, then 80 mg for 8 months</description>
    <arm_group_label>simvastatin</arm_group_label>
    <other_name>Zocor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching tablet each night for 9 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 35 to 69

          -  Parent with Alzheimer's disease

        Exclusion Criteria:

          -  Current use of cholesterol-lowering medication

          -  Active liver disease

          -  History of adverse reaction to statins

          -  Contraindication to lumbar puncture

          -  Elevated lab values (creatine kinase and creatinine)

          -  Use of medications known to interact with statins

          -  History of dementia

          -  Currently pregnant or planning to become pregnant

          -  Use of large quantities of grapefruit juice (more than 1 quart per day)

          -  Current involvement in another investigational drug study

          -  Contraindications to MRI (for MRI sub-study)

          -  Ethical contraindication to placebo (persons with high vascular risk)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia M. Carlsson, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://adrc.wisc.edu/</url>
    <description>Wisconsin Alzheimer's Disease Research Center</description>
  </link>
  <reference>
    <citation>Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T. Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A. 2001 May 8;98(10):5856-61. Epub 2001 Apr 10.</citation>
    <PMID>11296263</PMID>
  </reference>
  <reference>
    <citation>Wolozin B. A fluid connection: cholesterol and Abeta. Proc Natl Acad Sci U S A. 2001 May 8;98(10):5371-3.</citation>
    <PMID>11344276</PMID>
  </reference>
  <reference>
    <citation>Johnson NA, Jahng GH, Weiner MW, Miller BL, Chui HC, Jagust WJ, Gorno-Tempini ML, Schuff N. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology. 2005 Mar;234(3):851-9.</citation>
    <PMID>15734937</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2007</study_first_submitted>
  <study_first_submitted_qc>June 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2007</study_first_posted>
  <results_first_submitted>November 16, 2012</results_first_submitted>
  <results_first_submitted_qc>October 1, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 5, 2015</results_first_posted>
  <last_update_submitted>October 1, 2015</last_update_submitted>
  <last_update_submitted_qc>October 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>amyloid protein</keyword>
  <keyword>apolipoprotein</keyword>
  <keyword>cerebrospinal fluid</keyword>
  <keyword>cerebrovascular circulation</keyword>
  <keyword>inflammation</keyword>
  <keyword>magnetic resonance imaging</keyword>
  <keyword>prevention &amp; control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Middle-aged adults with parental history of Alzheimer's disease were recruited for this single-site trial (Madison, Wisconsin) from the Wisconsin Registry for Alzheimer's Prevention (WRAP) or the community through newsletters, websites, educational talks, health fairs, local clinics, and newspaper and magazine advertisements.</recruitment_details>
      <pre_assignment_details>103 participants enrolled in the trial and 100 were randomized to treatment (1 no longer met inclusion criteria, 2 declined participation).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Simvastatin</title>
          <description>Simvastatin 40 mg tablet nightly for 1 month then 80 mg tablet nightly for 8 months</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matching placebo tablet nightly for 9 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51">50 received assigned intervention (1 withdrew during baseline) 27 in MRI sub-study</participants>
                <participants group_id="P2" count="49">23 in MRI sub-study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49">27 completed MRI sub-study</participants>
                <participants group_id="P2" count="46">21 completed MRI sub-study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Simvastatin</title>
          <description>Simvastatin 40 mg tablet nightly for 1 month then 80 mg tablet nightly for 8 months</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matching placebo tablet nightly for 9 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.3" spread="7.4"/>
                    <measurement group_id="B2" value="52.4" spread="8.5"/>
                    <measurement group_id="B3" value="52.8" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.1" spread="2."/>
                    <measurement group_id="B2" value="16.3" spread="3.2"/>
                    <measurement group_id="B3" value="16.2" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mini Mental State Exam</title>
          <description>0-30 points score range where higher scores represent better outcomes; &lt;24 points indicate cognitive dysfunction.</description>
          <units>points</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.5" spread="0.8"/>
                    <measurement group_id="B2" value="29.6" spread="0.6"/>
                    <measurement group_id="B3" value="29.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein E4 carrier</title>
          <description>Apolipoprotein E4 is a genetic risk factor for Alzheimer's disease, which increases your risk of developing Alzheimer's disease by 2-10 fold depending on if you're a carrier of the allele.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total cholesterol</title>
          <description>Measured by nuclear magnetic resonance (NMR) spectroscopy</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="192.8" spread="36.4"/>
                    <measurement group_id="B2" value="187.6" spread="27.7"/>
                    <measurement group_id="B3" value="190.3" spread="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High-sensitivity c-reactive protein</title>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.59" spread="3.71"/>
                    <measurement group_id="B2" value="2.03" spread="2.21"/>
                    <measurement group_id="B3" value="2.32" spread="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cerebrospinal fluid beta-amyloid-42</title>
          <description>Primary outcome measured by xMAP; secondary analyses included measurement by Triplex method as well.</description>
          <units>ng/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="345.6" spread="77.1"/>
                    <measurement group_id="B2" value="331.0" spread="83.7"/>
                    <measurement group_id="B3" value="338.7" spread="80.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Cerebrospinal Fluid (CSF) Beta-amyloid-42</title>
        <time_frame>baseline and 9 months</time_frame>
        <population>1 participant declined follow up CSF collection in simvastatin arm; CSF could not be accessed at month 9 in 1 participant in placebo arm</population>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>Simvastatin 40 mg tablet nightly for 1 month then 80 mg tablet nightly for 8 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet nightly for 9 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cerebrospinal Fluid (CSF) Beta-amyloid-42</title>
          <population>1 participant declined follow up CSF collection in simvastatin arm; CSF could not be accessed at month 9 in 1 participant in placebo arm</population>
          <units>ng/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="44.1"/>
                    <measurement group_id="O2" value="-3.1" spread="38.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.966</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Regional Cerebral Blood Flow on MRI</title>
        <description>Mean changes noted in posterior cingulate cortex</description>
        <time_frame>baseline and 9 months</time_frame>
        <population>Number of participants analyzed represent participants in MRI substudy with readable MRI scans at both baseline and 9 months; 24 and 17 readable MRI scans in simvastatin and placebo arms, respectively. Unusable MRI scans resulted from poor quality images due to technical problems.</population>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>Simvastatin 40 mg tablet nightly for 1 month then 80 mg tablet nightly for 8 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet nightly for 9 months</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Regional Cerebral Blood Flow on MRI</title>
          <description>Mean changes noted in posterior cingulate cortex</description>
          <population>Number of participants analyzed represent participants in MRI substudy with readable MRI scans at both baseline and 9 months; 24 and 17 readable MRI scans in simvastatin and placebo arms, respectively. Unusable MRI scans resulted from poor quality images due to technical problems.</population>
          <units>mL/100 g/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.09" spread="6.69"/>
                    <measurement group_id="O2" value="-5.08" spread="8.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Inflammatory Markers</title>
        <description>Change noted in serum high-sensitivity c-reactive protein</description>
        <time_frame>baseline and 9 months</time_frame>
        <population>2 participants in the simvastatin arm and 3 participants in the placebo arm had incomplete hs-CRP results</population>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>Simvastatin 40 mg tablet nightly for 1 month then 80 mg tablet nightly for 8 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet nightly for 9 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inflammatory Markers</title>
          <description>Change noted in serum high-sensitivity c-reactive protein</description>
          <population>2 participants in the simvastatin arm and 3 participants in the placebo arm had incomplete hs-CRP results</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.16" spread="3.55"/>
                    <measurement group_id="O2" value="-0.31" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.113</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Cognitive Performance</title>
        <description>Change in Hopkins Verbal Learning Test Delayed Recall
The Hopkins Verbal Learning Test Delayed Recall score is the raw number of words recalled at Trial 4, adjusted for years of education and age. This is a 12-item word list test.</description>
        <time_frame>Baseline and 9 months</time_frame>
        <population>1 participant in simvastatin arm with missing data</population>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>Simvastatin 40 mg tablet nightly for 1 month then 80 mg tablet nightly for 8 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet nightly for 9 months</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Cognitive Performance</title>
          <description>Change in Hopkins Verbal Learning Test Delayed Recall
The Hopkins Verbal Learning Test Delayed Recall score is the raw number of words recalled at Trial 4, adjusted for years of education and age. This is a 12-item word list test.</description>
          <population>1 participant in simvastatin arm with missing data</population>
          <units>adjusted words recalled</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="1.38"/>
                    <measurement group_id="O2" value="0.26" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.210</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Simvastatin</title>
          <description>Simvastatin 40 mg tablet nightly for 1 month then 80 mg tablet nightly for 8 months</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matching placebo tablet nightly for 9 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated liver transaminases (&gt;2 times upper limit of normal)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated creatine kinase (CK) (&gt; 2 times upper limit of normal)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety/depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Cynthia M. Carlsson, MD, MS</name_or_title>
      <organization>University of Wisconsin School of Medicine and Public Health</organization>
      <phone>608-280-7000</phone>
      <email>cmc@medicine.wisc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

